Gil M. Labrucherie
2021
In 2021, Gil M. Labrucherie earned a total compensation of $5.3M as Chief Operating Officer and Chief Financial Officer at Nektar Therapeutics, which was about the same as previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $679,650 |
|---|---|
| Option Awards | $1,397,498 |
| Salary | $788,000 |
| Stock Awards | $2,391,094 |
| Other | $23,314 |
| Total | $5,279,556 |
Labrucherie received $2.4M in stock awards, accounting for 45% of the total pay in 2021.
Labrucherie also received $679.7K in non-equity incentive plan, $1.4M in option awards, $788K in salary and $23.3K in other compensation.
Rankings
In 2021, Gil M. Labrucherie's compensation ranked 2,456th out of 12,405 executives tracked by ExecPay. In other words, Labrucherie earned more than 80.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,456 out of 12,405 | 80th |
Division Manufacturing | 974 out of 5,494 | 82nd |
Major group Chemicals And Allied Products | 373 out of 2,369 | 84th |
Industry group Drugs | 325 out of 2,090 | 84th |
Industry Pharmaceutical Preparations | 214 out of 1,537 | 86th |
Source: SEC filing on April 29, 2022.
Labrucherie's colleagues
We found four more compensation records of executives who worked with Gil M. Labrucherie at Nektar Therapeutics in 2021.
2021
Howard Robin
Nektar Therapeutics
Chief Executive Officer
2021
Jonathan Zalevsky
Nektar Therapeutics
Senior Vice President and Chief Research and Development Officer
2021
John Northcott
Nektar Therapeutics
Senior Vice President and Chief Commercial Officer
2021
Mark Wilson
Nektar Therapeutics